$0.65
0.49% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US79400X1072
Symbol
SLRX

Salarius Pharmaceuticals Inc Stock price

$0.65
-0.20 23.78% 1M
-12.83 95.16% 6M
+0.00 0.49% YTD
-25.45 97.50% 1Y
-182.95 99.64% 3Y
-3,389.35 99.98% 5Y
-935,999.35 100.00% 10Y
-1,121,249.35 100.00% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.00 0.49%
ISIN
US79400X1072
Symbol
SLRX
Industry

Key metrics

Basic
Market capitalization
$4.2m
Enterprise Value
$-650.0k
Net debt
positive
Cash
$4.8m
Shares outstanding
940.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
1.0
Financial Health
Equity Ratio
50.0%
Return on Equity
-368.8%
ROCE
-119.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-5.1m | -
EBIT
$-5.1m | $-6.2m
Net Income
$-5.0m | $-8.8m
Free Cash Flow
$-4.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
2.9% | -
EBIT
2.8% | -9.1%
Net Income
-0.2% | -57.5%
Free Cash Flow
16.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-10.4
FCF per Share
$-4.7
Short interest
3.2%
Employees
2
Rev per Employee
$0.0
Show more

Is Salarius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Salarius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

Hold
50%
Sell
50%

Financial data from Salarius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.64 4.64
2% 2%
-
- Research and Development Expense 0.43 0.43
34% 34%
-
-5.06 -5.06
3% 3%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.07 -5.07
3% 3%
-
Net Profit -5 -5
0% 0%
-

In millions USD.

Don't miss a Thing! We will send you all news about Salarius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Salarius Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
15 days ago
HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statem...
Neutral
GlobeNewsWire
16 days ago
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term sharehold...
Neutral
GlobeNewsWire
about one month ago
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP 3 ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP 3 ACT's demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to addre...
More Salarius Pharmaceuticals Inc News

Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Head office United States
CEO David Arthur
Employees 2
Founded 2014
Website salariuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today